Lana Langendries

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity

Suzanne J. F. Kaptein, Sofie Jacobs, Lana Langendries et al. · Proceedings of the National Academy of Sciences · 2020 · 287 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

Rana Abdelnabi, Caroline S. Foo, Suzanne J. F. Kaptein et al. · EBioMedicine · 2021 · 145 citations · Full text

Pharmacy, Infectious Diseases, Infectious Disease Pharmacotherapy +16

An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models

Bert Schepens, Loes van Schie, Wim Nerinckx et al. · Science Translational Medicine · 2021 · 67 citations · Full text

Pharmacy, Immunology, Infectious Diseases +17

Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial

Laurens Liesenborghs, Isabel Spriet, Dirk Jochmans et al. · EBioMedicine · 2021 · 34 citations · Full text

Medicine, Infectious Diseases, Pharmacology +7

Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine

Suzanne J. F. Kaptein, Sofie Jacobs, Lana Langendries et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 31 citations · Full text

Medicine, Infectious Diseases, Pharmacology +12